The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | Checkpoint inhibition in the treatment of MPNs
Gabriela Hobbs, MD, Massachusetts General Hospital, Boston, MA, discusses the promising potential of checkpoint inhibition in the treatment of myeloproliferative neoplasms. Dr Hobbs highlights the results from a recent study which investigated the use of pembrolizumab in patients with myelofibrosis (MF), which unfortunately did not have any responses, but did result in activation and expansion of T-cells. Dr Hobbs concludes by mentioning the importance of continuing to investigate checkpoint inhibition in MPNs, especially at an earlier stage in the disease. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.
